New antibody EB070 begins first human safety trial
NCT ID NCT07413536
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of a new drug called EB070, an antibody that blocks a protein involved in allergic inflammation. Thirty-six healthy adults will receive a single injection of either EB070 or a placebo at increasing doses. The study monitors side effects and how the body processes the drug over about 3.5 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EB070 (anti-TSLP monoclonal antibody)
What this could lead to
If safe, this could pave the way for testing EB070 as a treatment for allergic or inflammatory conditions like asthma.
What could go wrong
This is an early Phase 1 safety study in healthy people, not patients. It cannot show if the drug works for any disease, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.